Abstract
Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus it is a promising target for the treatment of Type 2 Diabetes mellitus (T2DM). Inhibition of plasma DPP IV enzyme leads to enhanced endogenous GLP-1 and GIP activity, which ultimately results in the potentiation of insulin secretion by pancreatic β-cells and subsequent lowering of blood glucose levels, HbA[1c], glucagon secretion and liver glucose production. Various classes of structurally different DPP IV inhibitors are currently being explored and few of them such as Sitagliptin and Vildagliptin were successfully launched. These drugs have been approved as a once-daily oral monotherapy or as a combination therapy with current anti-diabetic agents like pioglitazone, glibenclamide, metformin etc. for the treatment of T2DM. Several other novel DPP IV inhibitors are in pipeline. The present review summarizes the latest preclinical and clinical trial data of different DPP IV inhibitors with a special emphasis on their DPP8/9 fold selectivity and therapeutic advantages over GLP-1 based approach.
Keywords: DPP IV, GLP-1, T2DM, developmental progress, sitagliptin, vildagliptin, alogliptin, selectivity
Current Drug Targets
Title: Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
Volume: 10 Issue: 1
Author(s): Rajesh Gupta, Sameer S. Walunj, Ranjeet K. Tokala, Kishore V.L. Parsa, Santosh Kumar Singh and Manojit Pal
Affiliation:
Keywords: DPP IV, GLP-1, T2DM, developmental progress, sitagliptin, vildagliptin, alogliptin, selectivity
Abstract: Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus it is a promising target for the treatment of Type 2 Diabetes mellitus (T2DM). Inhibition of plasma DPP IV enzyme leads to enhanced endogenous GLP-1 and GIP activity, which ultimately results in the potentiation of insulin secretion by pancreatic β-cells and subsequent lowering of blood glucose levels, HbA[1c], glucagon secretion and liver glucose production. Various classes of structurally different DPP IV inhibitors are currently being explored and few of them such as Sitagliptin and Vildagliptin were successfully launched. These drugs have been approved as a once-daily oral monotherapy or as a combination therapy with current anti-diabetic agents like pioglitazone, glibenclamide, metformin etc. for the treatment of T2DM. Several other novel DPP IV inhibitors are in pipeline. The present review summarizes the latest preclinical and clinical trial data of different DPP IV inhibitors with a special emphasis on their DPP8/9 fold selectivity and therapeutic advantages over GLP-1 based approach.
Export Options
About this article
Cite this article as:
Gupta Rajesh, Walunj S. Sameer, Tokala K. Ranjeet, Parsa V.L. Kishore, Singh Kumar Santosh and Pal Manojit, Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes, Current Drug Targets 2009; 10 (1) . https://dx.doi.org/10.2174/138945009787122860
DOI https://dx.doi.org/10.2174/138945009787122860 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Current and Future Therapeutic Strategies in NAFLD
Current Pharmaceutical Design Advances in Current Diabetes Proteomics: From the Perspectives of Label- free Quantification and Biomarker Selection
Current Drug Targets Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Therapy to Improve High-Density Lipoprotein Metabolism and Function
Current Pharmaceutical Design Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics
Current Drug Targets Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Definition of Postprandial Lipaemia
Current Vascular Pharmacology Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Vitamin D Deficiency and Oxidative Stress in Type 2 Diabetic Population of India
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery